A groundbreaking pilot study suggests a new blood-filtering therapy may offer a promising treatment for preeclampsia, a severe pregnancy complication characterized by high blood pressure. This innovative approach aims to reduce circulating levels of a specific placental protein linked to the condition.
Currently, the only definitive treatment for preeclampsia is delivery, which can lead to premature birth and associated health issues for the infant, and significant risks for the mother, including damage to vital organs. This new therapy, called apheresis, removes a protein known as soluble fms-like tyrosine kinase-1 (sFlt-1) from the blood. Elevated sFlt-1 levels are implicated in the vascular damage associated with preeclampsia.
Initial trials on baboons showed a significant reduction in sFlt-1. Subsequently, a small group of 16 pregnant individuals with preterm preeclampsia underwent the therapy. The study confirmed the treatment's safety and indicated a potential to prolong pregnancies, with treated participants carrying their pregnancies for a median of 10 days longer compared to an untreated historical group.
Researchers emphasize that while promising, further large-scale clinical trials are necessary to validate the treatment's efficacy and optimal use in managing preeclampsia and preventing premature deliveries.